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Insulin resistance leads to hypertriglyceridemia and
hepatic steatosis and is associated with increased
SREBP-1c, a transcription factor that activates fatty
acid synthesis. Here, we show that steatosis in
insulin-resistant ob/ob mice was abolished by dele-
tion of Scap, an escort protein necessary for gener-
ating nuclear isoforms of all three SREBPs. Scap
deletion reduced lipid synthesis and prevented fatty
livers despite persistent obesity, hyperinsulinemia,
and hyperglycemia. Scap deficiency also prevented
steatosis in mice fed high-fat diets. Steatosis was
also prevented when siRNAs were used to silence
Scap in livers of sucrose-fed hamsters, a model of
diet-induced steatosis and hypertriglyceridemia.
This silencing reduced all three nuclear SREBPs,
decreasing lipid biosynthesis and abolishing
sucrose-induced hypertriglyceridemia. These results
demonstrate that SREBP activation is essential
for development of diabetic hepatic steatosis and
carbohydrate-induced hypertriglyceridemia, but not
insulin resistance. Inhibition of SREBP activation has
therapeutic potential for treatment of hypertriglyceri-
demia and fatty liver disease.
INTRODUCTION
SREBPs are transcription factors that activate the synthesis of
fatty acids (FAs), triglycerides (TGs), and cholesterol in all organs
(Horton et al., 2002). In liver, hyperactivation of SREBPs causes
TG accumulation (Shimomura et al., 1999a), producing the path-
ological condition known as hepatic steatosis, which can lead to
cirrhosis and liver failure (Cohen et al., 2011). In liver, the primary
activator of SREBPs is insulin, which increases the synthesis and
proteolytic processing of one of the three SREBP isoforms,
namely SREBP-1c (Brown and Goldstein, 2008; Shimomura
et al., 1999b). The most frequent cause of hepatic steatosis is
obesity, which leads to insulin resistance and a compensatory240 Cell Metabolism 15, 240–246, February 8, 2012 ª2012 Elsevier Inincrease in plasma insulin. In rodentmodels of obesity, a paradox
arises. Although the liver resists one action of insulin—namely,
suppression of gluconeogenesis, it remains sensitive to the other
action—namely, stimulation of SREBP-1c (Brown andGoldstein,
2008). Thus, when insulin levels rise, the hormone hyperactivates
SREBP-1c and hepatic steatosis ensues.
SREBPs are synthesized as membrane-bound precursors in
the endoplasmic reticulum (ER) that must be processed in order
to activate transcription (Brown and Goldstein, 2009). Immedi-
ately after synthesis, SREBPs form complexes with Scap, an
ER-to-Golgi transport protein. In the Golgi, SREBPs are pro-
cessed sequentially by two proteases that release the tran-
scriptionally active fragment of SREBPs. The released SREBP
fragments enter the nucleus where they activate transcription
of all genes necessary to convert acetyl-CoA to FAs and choles-
terol (Horton et al., 2002). Scap is essential for SREBP process-
ing. In cultured cells lacking Scap (Rawson et al., 1999) and in
livers of Scap knockout mice (Matsuda et al., 2001), SREBP
precursors are rapidly degraded, and they never reach the Golgi
for processing and thus never enter the nucleus.
The SREBP family includes three isoforms with separate, but
overlapping functions. SREBP-1a activates cholesterol and FA
synthesis. It is abundant in growing cells, but is expressed at
relatively low levels in liver (Shimomura et al., 1997). SREBP-1c,
abundant in liver, primarily activates FA synthesis, while the
other abundant hepatic isoform, SREBP-2, activates cholesterol
production (Horton et al., 2002). SREBP-2 also activates the
gene encoding the LDL receptor (LDLR), which increases
cholesterol uptake into liver, and PCSK9, a secreted protein
that degrades hepatic LDLRs, thereby reducing cholesterol
uptake (Horton et al., 2009).
Although previous studies, largely correlative in nature, have
postulated a central role for SREBPs in obesity-induced TG
accumulation in liver and blood, the hypothesis has not been
tested rigorously for two reasons: (1) at high levels of expression,
SREBP-2 can activate FA synthesis (Horton et al., 1998); and (2)
selective knockout of the SREBP-1c isoform or both SREBP-1a
and -1c isoforms results in a marked compensatory increase in
SREBP-2 expression in livers of mice, thus blocking the overall
effect on FA synthesis (Liang et al., 2002; Shimano et al., 1997).
The logical way to test the SREBP hypothesis is to eliminate all
SREBPs in liver and then determine whether this ameliorates TGc.
Figure 1. Liver Protein and mRNA Levels in WT, L-Scap–, ob/ob, and
ob/ob;L-Scap– Mice
(A and B)Mice used are described in Table S1. (A) Livermembrane and nuclear
extract proteins were prepared from five to six mice per group. Equal aliquots
from each mouse were pooled (total, 20 mg for membranes and 30 mg for
nuclear extracts) and subjected to 8% SDS-PAGE and immunoblot analysis.
LRP and CREB proteins were used as loading controls for membrane and
nuclear extract fractions, respectively. P, membrane precursor; N, nuclear
form. (B) Total RNA was isolated from each mouse liver and subjected to
quantitative real-time PCR using b-actin as the invariant control. Each value
represents mean ± SEM of five to six mice relative to WT controls, which was
arbitrarily defined as 1.0. Statistical analysis was performed with two-tailed
Student’s t test. ACC-1, acetyl-CoA carboxylase-1; FAS, fatty acid synthase;
Elovl6, elongation of very long chain fatty acids 6; SCD-1, stearoyl-CoA
desaturase-1; HMG-CoA Syn, HMG-CoA synthase; HMG-CoA Red, HMG-
CoA reductase.
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Inasmuch as the functions of the three SREBP isoforms partially
overlap, removal of all SREBP actions in liver would require the
elimination of all three SREBP isoforms. In the current studies,
we eliminated all nuclear SREBPs at once by deleting the Scap
protein, which is required for all SREBP processing. We used
two approaches in two animal models: (1) liver-specific deletion
of Scap by homologous recombination in ob/obmice, an animal
model of severe obesity, insulin resistance, and hepatic steato-
sis; and (2) knockdown of Scap mRNA through RNAi in livers
of sucrose-fed hamsters, a model of carbohydrate-induced
hypertriglyceridemia (Avramoglu et al., 2003; Taghibiglou et al.,
2000). The combined results provide strong evidence for an
essential role of SREBPs in activating pathological lipogenesis
in response to hyperinsulinemia or carbohydrate overload.
RESULTS
Deletion of SREBP-1c Only Partially Reduces Liver Fat
in ob/ob Mice
In humans and mice with insulin resistance and hepatic steato-
sis, SREBP-1c levels and FA synthesis rates are elevated in liver
(Donnelly et al., 2005; Higuchi et al., 2008; Shimomura et al.,
1999a). To determine if blocking SREBP-1c activity is sufficient
to prevent the development of hepatic steatosis in insulin-
resistant states, we deleted SREBP-1c from ob/ob mice, which
become massively obese and insulin resistant owing to a muta-
tion in leptin (Zhang et al., 1994). Unexpectedly, inactivation of
the Srebp-1c isoform in ob/ob mice reduced hepatic FA
synthesis and TG content by only 50% (Figure S1). This partial
reduction in liver TG had no impact on plasma insulin, glucose, or
body weights of ob/ob mice (data not shown).
Liver-Specific Deletion of Scap Prevents Hepatic
Steatosis in ob/ob Mice
To determine if blocking all SREBP activity in liver is required to
prevent the induction of lipogenesis and hepatic steatosis in an
insulin-resistant state, we used a previously described line of
mice with floxed Scap alleles (Matsuda et al., 2001). We bred
these mice with albumin-Cre transgenic mice to achieve liver-
specific inactivation of Scap (L-Scap). L-Scap mice were
crossed with ob/ob mice to generate ob/ob;L-Scap mice.
Scap was undetectable in immunoblots of liver extracts from
L-Scap and ob/ob;L-Scap mice (Figure 1A). Immunoblotting
with an antibody that detects both SREBP-1a and -1c revealed
an elevation in the nuclear SREBP-1 in ob/ob mice. Previous
studies showed that this is attributable to an increase in the
synthesis and processing of SREBP-1c, which is stimulated by
hyperinsulinemia in thesemice (Shimomura et al., 1999a; Shimo-
mura et al., 1999b). Nuclear forms of all SREBPs were not
detectable in any of the Scap-deficient mice. The membrane-
bound SREBP precursors were also markedly reduced in
L-Scapmice, in part because of a 90% reduction in SREBP-1c
mRNA and a 50% reduction in SREBP-2 mRNA (Table S1). It is
also likely that the precursors were rapidly degraded as previ-
ously observed in Scap-deficient CHO cells (Rawson et al.,
1999).
As previously reported for ob/ob mice, mRNAs for FA
synthetic enzymes ACC-1 and FAS were markedly elevated inCell Mob/ob mouse livers (Shimomura et al., 1999a; Shimomura
et al., 1999b), and this increase was abolished in ob/ob;L-Scap
mice (Figure 1B). ThemRNAs for other SREBP target geneswere
also reduced. These included elongation of very long chain fatty
acids 6 (Elovl6), stearoyl CoA desaturase-1 (SCD-1), HMG-CoA
synthase, and HMG-CoA reductase (Figure 1B).
To confirm the functional significance of themRNA reductions,
we measured hepatic FA synthesis in vivo using 3H-water
(Figure 2A). FA synthesis was markedly elevated in livers of
ob/ob mice, and this was reduced by nearly 90% when Scap
was absent. We noted that Scap deficiency also lowered FA
synthesis even in WT mice. Liver TG content was elevated by
10-fold in ob/ob mice, reflecting severe hepatic steatosis (Fig-
ure 2B). Remarkably, these levels were reduced to normal in
ob/ob;L-Scap mice. Scap deficiency also reduced hepatic
TGs in WT mice. Liver weights were increased in ob/ob mice
and were reduced toward normal in ob/ob;L-Scap mice
(Figures 2C and 2D). The enlarged livers of ob/ob mice were
pale in color, owing to TG accumulation (Figure 2G). The color
was normalized in ob/ob;L-Scap mice (Figure 2H).etabolism 15, 240–246, February 8, 2012 ª2012 Elsevier Inc. 241
Figure 2. Liver-Specific Deletion of Scap Blocks
FA Synthesis and Prevents Hepatic Steatosis in
ob/ob Mice
(A) In vivo synthesis rates of FAs in livers of WT, L-Scap,
ob/ob, and ob/ob;L-Scap mice. Chow-fed male mice
(16 weeks old) of the indicated genotype were injected
intraperitoneally with 3H-labeled water (50 mCi in 0.25 ml
of isotonic saline). One hr later, liver was removed for
measurement of 3H-labeled FAs as described (Shimano
et al., 1996). Rates of FA synthesis were calculated as
mmoles of 3H-radioactivity incorporated into FAs per hr per
g liver. Each bar represents mean ± SEM of values from
four to six mice.
(B) TG concentrations in livers of 12-week-old male mice
with the indicated genotypes. Mice used were those
described in Table S1. Each bar represents mean ± SEM
of data from five to six mice.
(C) Liver weights of mice in (B).
(D) Body weights of mice in (B).
(E) Plasma insulin concentrations of mice in (B).
(F) Plasma glucose concentrations of mice in (B).
(G–I) Representative photographs of 20-week-old ob/ob
(G) and ob/ob;L-Scap (H), and WT (I) mice.
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parameters in the mice under study. Although Scap deficiency
abolished overproduction of TGs in ob/ob livers, it had no effect
on food intake or body weight. At 12 weeks of age, body weights
were similarly elevated in ob/ob and ob/ob;L-Scap mice (53.2
and 47.4 g, respectively, compared with 26.5 g in WT mice)
(Figure 2D). Total fat mass was also similar in ob/ob and
ob/ob;L-Scapmice (49.9% and 49.4% of body weight, respec-
tively, compared with 9.3% in WT mice) (Table S1). Plasma
insulin levels remained markedly elevated (47-fold and 34-fold242 Cell Metabolism 15, 240–246, February 8, 2012 ª2012 Elsevier Inc.in ob/ob and ob/ob;L-Scap, respectively) (Fig-
ure 2E). Despite the massive increase in plasma
insulin, plasma glucose was slightly elevated in
both ob/ob lines as compared with WT (Fig-
ure 2F), indicating massive resistance to the
glucose-lowering effects of insulin.
To confirm that insulin resistance was not
altered by deleting Scap, glucose and insulin
tolerance tests were performed. We found
nearly identical impairment to both challenges
in ob/ob and ob/ob;L-Scap mice (Figures
S2A and S2B). Hyperinsulinemia present in ob/
ob and ob/ob;L-Scap mice also failed to sup-
press the expression of the gluconeogenic
genes PEPCK and glucose 6-phosphatase
(Table S1), again indicating a persistence of
insulin resistance.
We next examined whether deletion of Scap
also prevents hepatic steatosis, which develops
in obesity induced by a high-fat diet (HFD). For
these studies, we used a previously described
inducible liver deletion of Scap that was
mediated by Cre driven by the MX1 promoter
(L-Scap;MX1-Cre) (Matsuda et al., 2001).
Chow-fed WT and L-Scap;MX1-Cre mice
(male, 12 weeks old) were treated with fourintraperitoneal injections of 300 mg polyI:polyC (1mg/ml in water)
administered every 2 days to activate the MX-1 promoter and
induce Cre expression in liver (Matsuda et al., 2001). After the
final injection, mice were either continued on chow or fed
a HFD containing 58% kcal lard and 25.6% kcal carbohydrates
for 4 months prior to study. In WT mice, the HFD increased liver
TG content 6-fold (from 24 to 142 mg/g) and cholesterol content
2.4-fold (from 2.2 to 5.2 mg/g) (Figures S2C and S2D). In
contrast, L-Scapmice fed the HFD had liver TG and cholesterol
concentrations that were not different from WT mice fed chow
Figure 3. RNAi-Mediated Silencing of Scap in Hamsters
(A and B) Hamsters used are described in Table S2. Hamsters were fed chow
or a high-sucrose diet for 7 weeks and injected with saline, siScap, or siScap-
mm on weeks 4 and 6. (A) Membrane and nuclear extract fractions prepared
individually from six to seven hamster livers per treatment group. Equal
aliquots of protein from each liver were pooled (total, 30 mg) and subjected to
8% SDS-PAGE and immunoblot analysis. LRP and CREB proteins were used
as loading controls for membrane and nuclear extract fractions, respectively.
P, membrane precursor; N, nuclear form. (B) Total RNAwas isolated from each
hamster liver and subjected to quantitative real-time PCR using b-actin as the
invariant control. Each value represents mean ± SEM relative to chow-fed
hamsters injected with saline, which was arbitrarily defined as 1.0 and shown
as a dashed line. *p < 0.01 denotes the level of statistical significance (two-
tailed Student’s t test) between saline- and siScap-injected hamsters fed the
sucrose diet.
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the HFD had similar elevations of plasma insulin and glucose
(Figures S2E and S2F).
RNAi Silencing of Scap Ameliorates Dyslipidemia
in Sucrose-Fed Hamsters
To determine whether liver Scap deficiency would reduce
plasma TGs in an animal model of carbohydrate-induced hyper-
triglyceridemia, we studied sucrose-fed hamsters. As compared
with mice, hamster lipoprotein metabolism more closely resem-
bles that in humans because hamsters, like humans, secrete
only apoB-100 containing VLDL from liver and because their
plasma contains cholesteryl ester transfer protein (CETP) (Taghi-
biglou et al., 2000). Previous studies showed that a high carbo-
hydrate diet raises the concentration of TGs in liver and plasma
of these animals (Avramoglu et al., 2003; Taghibiglou et al.,
2000). To eliminate hepatic Scap mRNA in hamsters, we deliv-
ered siRNA to liver by intravenous injection of siRNA complexed
with lipid nanoparticles (LNP) (Akinc et al., 2009). In prelimi-
nary experiments, we designed a series of Scap siRNAs and
screened them for their ability to decrease Scap mRNA in
primary hamster hepatocytes. The most potent siRNA reduced
Scap mRNA by more than 80%, and this was used for in vivo
studies (designated siScap). As a control, we introduced four
mutations into siScap to generate a mismatch version that did
not reduce Scap mRNA (designated siScap-mm).
Hamsters were fed the high-sucrose diet for 7 weeks. On
weeks 4 and 6 of the diet, hamsters were injected intravenously
with saline or 2.5 mg/kg body weight of LNP-formulated siScap
or siScap-mm. siScap reduced liver Scap mRNA by 80%
(Table S2), and Scap protein was reduced below the limit of
detection by our antibody (Figure 3A). The precursor and nuclear
forms of SREBP-1 and -2 were also markedly reduced (Fig-
ure 3A). Although LDLR mRNA was reduced by siScap (Fig-
ure 3B), the level of LDLR protein did not decline (Figure 3A).
LDLR preservation is likely attributable to the marked reduction
in the mRNA encoding PCSK9 in these animals (Figure 3B).
PCSK9 is a protein that destroys hepatic LDLRs (Horton et al.,
2009). PCSK9 and LDLR are both activated by SREBP-2 (Horton
et al., 2003).
In the sucrose-fed hamsters, mRNAs for FAS and SCD-1, two
targets of SREBP-1c, were elevated when compared to controls
(indicated by the dashed line in Figure 3B). These mRNAs were
reduced to normal by siScap. siScap also reduced the mRNA
for ACC-1, but the reduction did not reach the level of signifi-
cance at p < 0.01 (Table S2). The mRNAs for two cholesterol-
synthesizing enzymes, HMG-CoA synthase and HMG-CoA
reductase, were also reduced by siScap (Figure 3B). Control
siScap-mm had none of these effects.
Plasma TGs were elevated nearly 3-fold to 570 mg/dl in
sucrose-fed hamsters (Figure 4A). siScap reduced these levels
nearly to normal. Liver TGs were elevated more modestly, and
were reduced by siScap. siScap-mm had none of these effects.
Fractionation of plasma lipoproteins by fast performance liquid
chromatography (FPLC) revealed a marked reduction in VLDL-
TGs and VLDL-cholesterol in siScap-treated hamsters (Fig-
ure 4C). There was no significant change in LDL- or HDL-choles-
terol levels. In siScap-treated hamsters, VLDL secretion was
reduced by 40% as measured by the rate of increase in plasmaCell MTGs following administration of the lipoprotein lipase inhibitor
Tyloxapol (Figure 4D) (Schotz et al., 1957). As shown in
Table S2, siScap treatment of sucrose-fed hamsters did not
significantly affect body weight, plasma insulin levels, or blood
glucose levels. siSCAP, but not siSCAP-mm, produced a statis-
tically significant reduction in plasma free FA levels.
DISCUSSION
In the current studies, we show that elimination of nuclear
SREBPs in liver ameliorates pathologic TG accumulation in three
models: (1) ob/obmice, a model of insulin resistance, metabolic
syndrome, and diabetes; (2) HFD-induced insulin resistance; and
(3) sucrose-fed hamsters, a model of carbohydrate-induced
hypertriglyceridemia. Nuclear SREBPs were eliminated in liver
by a reduction in the mRNA encoding Scap, a protein that is
essential for the proteolytic activation of all SREBPs (Rawson
et al., 1999). As a result, there was a corresponding decline in
the mRNAs encoding essential enzymes of FA synthesis, all of
whose transcription is driven by SREBPs.
In ob/ob mice, elimination of the hepatic Scap gene by
homologous recombination produced a dramatic decline in FAetabolism 15, 240–246, February 8, 2012 ª2012 Elsevier Inc. 243
Figure 4. RNAi-Mediated Silencing of Scap Prevents Hepatic
Steatosis and Hyperlipidemia in Sucrose-Fed Hamsters
(A–C) Hamsters used in (A)–(C) are described in Table S2. (A) Plasma TG
concentrations in hamsters injected with saline, siScap-mm (control), or
siScap. Each value represents the mean ± SEM of six to seven hamsters. The
dashed line represents the level measured in hamsters fed standard chow. (B)
Liver TG concentrations of hamsters described in (A). (C) FPLC profiles of
plasma lipoproteins from hamsters injected with siScap-mm or siScap. Equal
aliquots of plasma from six to seven hamsters in each group was pooled and
subjected to gel filtration by FPLC. Concentrations of TGs and cholesterol in
each fraction were measured as described in Experimental Procedures.
(D) RNAi-mediated silencing of Scap reduces TG secretion from liver.
Hamsters were fed a high-sucrose diet for 7 weeks. On weeks 4 and 6,
hamsters were injected with 2.5 mg/kg body weight of LNP-formulated
siLuciferase (Control) or siScap. One week after the final injection, hamsters
were anesthetized with pentobarbital (40 mg/kg) and injected with 20%
Tyloxapol (600 mg/kg body weight). Blood samples were obtained at times
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244 Cell Metabolism 15, 240–246, February 8, 2012 ª2012 Elsevier Insynthesis and a reversal of hepatic steatosis. Improvement
occurred even though the ob/ob;L-Scap mice consumed
excess food just like the ob/ob mice, exhibited the same gross
obesity, and developed a similar massive degree of hyperinsuli-
nemia and glucose intolerance. These data demonstrate that
hepatic FA overproduction is not required for the development
of systemic insulin resistance in mice.
Given the reduction in hepatic FA synthesis in ob/ob;L-Scap
mice, some tissue must increase its FA synthesis in order for
these animals to accumulate the same excessive amount of
body fat stores as ob/ob mice. Previously, we showed that the
decreased hepatic FA synthesis in livers of L-Scap mice is
balanced by a compensatory increase in nonhepatic tissues,
primarily adipose tissue (Kuriyama et al., 2005). The same
compensatory increase also occurs in the white adipose tissue
of ob/ob;L-Scapmice. As shown in Table S1, the levels of lipo-
genic gene mRNAs in the epididymal fat pads of ob/ob;L-Scap
mice were increased by 1.6- to 2.5-fold compared to ob/ob
mice. In the sucrose-fed hamsters, the major manifestation
was a major increase in plasma VLDL-TGs with a lesser, but
significant, accumulation of fat in the liver. We lowered liver
Scap mRNA in these hamsters by injection of an siRNA that
targets Scap. As in the ob/ob mice, a reduction in hepatic
Scap led to an absence of detectable nuclear SREBPs in liver
and a reduction in the mRNAs encoding FA-synthesizing
enzymes. The rate of VLDL secretion from liver declined, and
plasma TGs returned nearly to normal. Thus, elimination of
nuclear SREBPs prevents the hypertriglyceridemia induced by
carbohydrate excess in hamsters.
The hamster studies help to answer a question raised by
earlier studies of hepatic SREBPs. Inasmuch as SREBP-2 acti-
vates the gene for the LDLR (Horton et al., 2002), it was theoret-
ically possible that a decrease in nuclear SREBP would lead to
an undesirable increase in plasma LDL. Indeed, we did observe
a fall in LDLR mRNA in the siScap-treated hamsters (Figure 3B),
but the LDLR protein did not decline (Figure 3A). We speculate
that LDLR protein levels were maintained because SREBP-2
also activates the gene encoding PCSK9, a protein that destroys
hepatic LDLRs (Horton et al., 2009). In mice, hepatic PCSK9
mRNA and plasma PCSK9 levels were reduced by more than
80% in L-Scap and ob/ob;L-Scap mice (Table S1). In the
siScap-treated hamster livers, the decline in PCSK9 mRNA
was at least as profound as the decline in LDLR mRNA. The
net result was that LDL-cholesterol did not change in the siScap-
treated hamsters (Figure 4C). If a similar result occurs in humans,
it would seem that blockade of hepatic nuclear SREBPs may not
lead to an undesirable decrease in LDLR protein or a rise in
plasma LDL cholesterol levels.
The relevance of the current studies to humans lies in the
observation that humans with hepatic steatosis manifest
elevated hepatic levels of SREBP-1c (Higuchi et al., 2008) and
increased rates of hepatic lipogenesis (Donnelly et al., 2005).
Thus, in humans Scap is a potential target for therapies aiming0 and 100 min following injection of Tyloxapol. The difference in plasma TG
concentrations between the two time points was used to calculate the rate of
TG secretion, which was expressed as mg/dl per hr. Each bar represents the
mean ± SEMof data from six hamsters. Statistical analysis was performedwith
the two-tailed Student’s t test.
c.
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a good target because so far its only known role is to escort
SREBPs to the Golgi. Nuclear SREBPs might also be eliminated
by inhibitors of the two proteases that process SREBPs, but this
approach is likely to lead to unwanted side effects, since these
proteases are required for processing of other proteins such as
ATF6 and the CREB-like proteins (Ye, 2011). Further human
studies will reveal whether Scap elimination has the same desir-
able effects in humans as it does in the two animal models
studied here.
EXPERIMENTAL PROCEDURES
Animals
Mice carrying the floxed Scap allele (Scapf/f) (Matsuda et al., 2001) were back-
crossed five times into the C57BL/6J background using Marker-Assisted
‘‘Speed’’ Congenics and crossed with Albumin-Cre transgenic mice (Jackson
Laboratory, No. 003574) to generate Scapf/f;Alb-Cre mice (designated
L-Scap). L-Scap mice were bred with lep+/ob heterozygous mice (Jackson
Laboratory, No. 000632) to produce L-Scap;lep+/ob mice, which were
crossed to each other to obtain ob/ob;L-Scap mice. All mice were housed
in colony cages with a 12 hr light/12 hr dark cycle and fed ad libitum Harlan
Teklad Rodent Diet 7002 prior to study. Golden Syrian hamsters (Harlan
Laboratories) were housed in colony cages and maintained on a 12 hr light/
12 hr dark cycle and fed Harlan Teklad Rodent Diet 7001 prior to initiation of
studies. All animal experiments were performed with approval of the Institu-
tional Animal Care and Research Advisory Committee at UT Southwestern.
Metabolic Parameters
Plasma and liver analytes were measured using previously published assays.
See Supplemental Experimental Procedures for details.
In Vivo siRNA Experiments
Sequence of siScap: 50-GCUUAAUGGUUCCCUUGAUTT-30 (sense) and
50-AUCAAGGGAACCAUUAAGCTT-30 (antisense). Sequence of siScap-mm:
50- GCUUAAUcGUaCCgUaGAUTT-30 (sense) and 50-AUCuAcGGuACgAUU
AAGCTT-30 (antisense), where the four mutations are denoted by lower cases.
For in vivo experiments, siRNA oligos were formulated in lipid nanoparticles
(LNP) (Frank-Kamenetsky et al., 2008). Golden Syrian hamsters (male, 90 g)
were fed an ad libitum chow diet (Harlan Teklad, No. 7001) or a high-sucrose
diet (MP Biomedicals diet, No. 90238) for a total of 7 weeks prior to study.
On weeks 4 and 6, hamsters were injected via jugular vein with saline or with
2.5 mg/kg body weight of LNP-formulated siScap or siScap-mm. One week
after the final injection, hamsters were fasted for 4 hr and euthanized with
saturating isoflurane to obtain plasma and tissues for analyses.
Quantitative Real-Time PCR
Total RNA was extracted from each liver using RNA STAT-60 (Tel-Test, Inc.)
and subjected to quantitative real-time PCR as described (Liang et al.,
2002). Primers for mouse genes were described previously (Liang et al.,
2002; Yang et al., 2001); primers for hamster genes are available upon
request.
Immunoblot Analyses of Liver Nuclear Extracts and Membrane
Fractions
Membrane and nuclear extract fractions were prepared from five to seven
mouse or hamster livers and equal aliquots from each were pooled (total,
20 mg for membranes and 30 mg for nuclear extracts) and subjected to 8%
SDS-PAGE and immunoblot analyses (Engelking et al., 2004; Matsuda et al.,
2001; Shimano et al., 1997).
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